

1-800-533-1710

<b>PATIENT NAME</b> TEST, TEST		<b>PATIENT NUMBER</b> L3MRNW4143510		<b>AGE</b> 55	<b>SEX</b> F	<b>ACCESSION #</b> W4143510
<b>ORDERING PHYSICIAN</b>		<b>CLIENT ORDER #</b>			<b>ACCOUNT #</b> LIAISONS	
<b>COLLECTION</b> 10/04/11 01:39 P	<b>RECEIVED</b> 10/04/11 01:39 P	<b>REPORT PRINTED</b> 10/04/11 02:17 P		<b>SPECIMEN INFORMATION</b> DATE OF BIRTH:		
<b>DATE</b> <b>TIME</b>	<b>DATE</b> <b>TIME</b>	<b>DATE</b> <b>TIME</b>				
Test Client Attn: Mayo Liaisons 200 First Street SW Rochester, MN 55905 507-284-8202						

TEST REQUESTED	HI	LO	REF RANGE	PERFORM SITE *
----------------	----	----	-----------	----------------

**Alpha Fetoprotein Total+L3 Percent**
**REPORTED: 10/04/11 01:39 P**

Alpha Fetoprotein Total	3	ng/mL	0-15	REF
Alpha Fetoprotein L3%	3	%	0.0-9.9	REF

**TEST INFORMATION:** Alpha Fetoprotein L3 Percent  
 The uTASWako method is used. Results obtained with different assay methods or kits cannot be used interchangeably.

The AFP-L3 Percent assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases.

Patients with elevated serum AFP-L3 percent should be more intensely evaluated for evidence of hepatocellular carcinoma since elevated values have been shown to be associated with a seven-fold increase in the risk for developing hepatocellular carcinoma within 21 months. For pregnant females, the result is not interpretable as a tumor marker.

Test Performed by: ARUP Laboratories, Inc.  
 500 Chipeta Way  
 Salt Lake City, UT 84108

\* PERFORMING SITE

<b>PATIENT NAME</b> TEST, TEST	<b>ORDER STATUS</b> Final	<b>COLLECTION DATE AND TIME</b> 10/04/11 01:39 P
-----------------------------------	------------------------------	---